CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions
Saar Gill, Jennifer N. Brudno
Abstract
At the time of writing, five anti-CD19 CAR T-cell products are approved by the U.S. Food and Drug Administration for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin lymphoma, pediatric B-cell acute lymphoblastic leukemia, and multiple myeloma. CAR T cells for chronic lymphocytic leukemia, acute myeloid leukemia, and less common malignancies such as T-cell lymphomas and Hodgkin lymphoma are being tested in early-phase clinical trials worldwide. The purpose of this overview is to describe the current landscape of CAR T cells in hematologic malignancies, outline their outcomes and toxicities, and explain the outstanding questions that remain to be addressed.
Topics & Concepts
MedicineLymphomaMultiple myelomaLymphoblastic lymphomaChronic lymphocytic leukemiaClinical trialAcute lymphocytic leukemiaLeukemiaOncologyCD19ImmunologyT cellCancer researchInternal medicineLymphoblastic LeukemiaAntigenImmune systemCAR-T cell therapy researchVirus-based gene therapy researchViral Infectious Diseases and Gene Expression in Insects